Stem Cell Therapy for Dry Age-Related Macular Degeneration: Your 2026 Guide to Vision Restoration

Explore the latest 2026 research on stem cell therapy for dry Age-Related Macular Degeneration (AMD). Learn how RPE cell transplantation and clinical trials offer new hope for restoring vision. Consult Cell La Vie.

Читать далее...

MSC Therapy for Burn Wounds and Chronic Skin Regeneration: 2026 Breakthroughs in Exosome-Based Healing

New 2026 research reveals UC-MSC exosomes combined with low-intensity pulsed ultrasound and curcumin-hydrogel systems achieve remarkable burn wound healing — including MRSA-infected wounds — through autophagy regulation, anti-scarring mechanisms, and immunomodulation. Five landmark papers reviewed.

Читать далее...

Stem Cells and Alzheimer’s Disease: A Patient’s Guide to What 2026 Research Shows

2026 patient guide to MSC therapy for Alzheimer’s disease: how it differs from lecanemab and donanemab, who is a candidate, what outcomes to expect, the 6 active clinical trials including NCT06775964 and the first MSC + antibody drug combination trial.

Читать далее...

The First FDA-Approved Stem Cell Therapy for Type 1 Diabetes: What Zimislecel Means for Patients in 2026

Zimislecel (VX-880) is the first stem cell-derived islet therapy to reach the FDA, and the September 2025 NEJM paper showed 12 of 12 patients achieving insulin independence. Here’s what it means for T1D patients in 2026, who qualifies, and what options exist in Thailand now.

Читать далее...

MSC Therapy for Degenerative Disc Disease: A 2026 Meta-Analysis of Randomized Trials and the Cell-Free Exosome Frontier

A 2026 meta-analysis of 7 randomized trials confirms intradiscal MSC injections reduce chronic back pain and disability significantly. Meanwhile, bioengineered exosome therapies are redefining what cell-free disc regeneration looks like.

Читать далее...

MSC Therapy for Peripheral Arterial Disease and Critical Limb Ischemia: 2026 Clinical and Mechanistic Breakthroughs

CRISPR-edited MSCs, iPSC-derived cells, combinatorial cell therapy, and exosome-based approaches are transforming PAD/CLI treatment. Six landmark 2026 papers and five active clinical trials reviewed for clinicians and researchers.

Читать далее...

MSC Therapy for Pulmonary Arterial Hypertension: Mechanisms, Mitochondrial Repair.

Pulmonary arterial hypertension kills half its patients within five years. 2026 research shows mesenchymal stem cells — especially HO-1-modified and mitochondria-primed MSCs — are reversing the vascular remodeling at the disease’s core. Here’s the science behind the breakthrough.

Читать далее...

Can Stem Cell Exosomes Restore Hearing? What the 2026 Breakthrough Means for You

A 2026 Phase 1 trial showed that MSC-derived exosomes injected into the ear were safe and improved hearing in patients with sudden sensorineural hearing loss. Here’s what the breakthrough means and when it could be available.

Читать далее...

How Much Does Stem Cell Therapy Cost in 2026? A Patient’s Realistic Guide

Stem cell therapy prices range from $2,000 to $100,000 depending on where you go. Here’s what actually drives the cost, what’s included, and how Thailand compares to the US, Australia, and Europe in 2026.

Читать далее...

Exosome Therapy for ALS: First-Ever Strength Improvement Reported in Clinical Trial

A 2025 clinical trial reports the first-ever strength improvement in ALS patients using intranasally delivered MSC exosomes — zero adverse events across 32 treatments.

Читать далее...
Top